Health Care · NYSE: MCK
McKesson earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends March · next results expected around 3 Feb 2027
Latest: Q2 FY2027
McKesson deepened its push into specialty and oncology care, extending its CVS Health distribution deal through June 2032 and agreeing to a roughly 49% stake in Option Care Health.
McKesson extended its pharmaceutical distribution partnership with CVS Health through June 2032. Growth came from specialty products sold to health systems and strategic accounts, and from provider solutions and specialty distribution in Oncology & Multispecialty. Prescription Technology Solutions grew on third-party logistics and access solutions, though hub dispensing contributed less. In Medical-Surgical Solutions, a weaker product mix in ambulatory care held back profit. PRISM Vision Group added Spectrum Vision Partners, bringing its network to more than 350 providers.
Read the Q2 FY2027 summary →Q2 FY2027 slides (PDF) ↗Official transcript (PDF) ↗
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q3 FY25 | $95.3B |
| Q4 FY25 | $90.8B * |
| Q1 FY26 | $97.8B |
| Q2 FY26 | $103.2B |
| Q3 FY26 | $106.2B |
| Q4 FY26 | $96.3B * |
| Q1 FY27 | $105.4B |
| Q2 FY27 | $111.0B |
Data
| Q3 FY25 | $6.95 |
| Q1 FY26 | $6.25 |
| Q2 FY26 | $8.92 |
| Q3 FY26 | $9.59 |
| Q1 FY27 | $5.15 |
| Q2 FY27 | $10.44 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q3 FY25 | 1.3% |
| Q4 FY25 | 1.8% |
| Q1 FY26 | 1.1% |
| Q2 FY26 | 1.4% |
| Q3 FY26 | 1.5% |
| Q4 FY26 | 2.2% |
| Q1 FY27 | 1.3% |
| Q2 FY27 | 1.4% |
Data
| Q3 FY25 | -$2.5B |
| Q4 FY25 | $7.6B |
| Q1 FY26 | -$1.0B |
| Q2 FY26 | $2.3B |
| Q3 FY26 | $1.1B |
| Q4 FY26 | $3.3B |
| Q1 FY27 | -$332.0M |
| Q2 FY27 | $3.0B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $95.3B | $90.8Bd | $97.8B | $103.2B | $106.2B | $96.3Bd | $105.4B | $111.0B |
| Gross margin | 3.4% | 4.0% | 3.4% | 3.4% | 3.5% | 4.2% | 3.5% | 3.6% |
| Operating income | $1.2B | $1.6Bd | $1.0B | $1.4B | $1.6B | $2.1Bd | $1.3B | $1.6B |
| Operating margin | 1.3% | 1.8% | 1.1% | 1.4% | 1.5% | 2.2% | 1.3% | 1.4% |
| Net income | $879.0M | $1.3Bd | $784.0M | $1.1B | $1.2B | $1.7Bd | $614.0M | $1.2B |
| Diluted EPS | $6.95 | — | $6.25 | $8.92 | $9.59 | — | $5.15 | $10.44 |
| Operating cash flow | -$2.4Bd | $7.7Bd | -$918.0M | $2.4Bd | $1.2Bd | $3.4Bd | -$220.0M | $3.1Bd |
| Capital expenditure | $126.0Md | $169.0Md | $111.0M | $106.0Md | $108.0Md | $111.0Md | $112.0M | $65.0Md |
| Free cash flow | -$2.5B | $7.6B | -$1.0B | $2.3B | $1.1B | $3.3B | -$332.0M | $3.0B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 4 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 5 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 8 May 202610-K for the period ended 31 Mar 2026SEC ↗
- 4 Feb 202610-Q for the period ended 31 Dec 2025SEC ↗
- 6 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 6 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 9 May 202510-K for the period ended 31 Mar 2025SEC ↗
- 6 Feb 202510-Q for the period ended 31 Dec 2024SEC ↗